What question did this study set out to answer?

This research aims to refine the risk stratification of myelodysplastic syndromes (MDS) in Brazil using molecular insights.

December 8, 2025BloodOpen Access

Molecular risk stratification of myelodysplastic syndromes in Brazil: A cohort applying IPSS-m and taxonomic classification

View Full Paper

Ask AI

Bookmark

Authors

Cohort analysis reveals improved risk stratification and survival outcomes in MDS patients, highlighting the role of next-generation sequencing.

This research aims to refine the risk stratification of myelodysplastic syndromes (MDS) in Brazil using molecular insights.
Conducted a retrospective cohort analysis of 114 MDS patients diagnosed at a private hospital in Brazil.
Applied next-generation sequencing, bone marrow evaluation, and conventional cytogenetics.
Classified cases using 2022 WHO/ICC and assessed risk using IPSS-R and IPSS-M.
Median overall survival for patients was 50.4 months, comparable with prior studies in Latin America.
Risk stratification showed 48.2% classified as high/very high risk by IPSS-R, with IPSS-M upstaging 18% of cases.
Significant prevalence of adverse mutations such as TP53-complex correlating with poorer overall survival.

Rocha et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Cohort analysis reveals improved risk stratification and survival outcomes in MDS patients, highlighting the role of next-generation sequencing.